SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 8

Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies

Arihant Senthil(University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India)0009-0008-0900-6333
Tashvin Paul(Avalon University School of Medicine, Willemstad, Curaçao)0009-0009-0165-3971
Karanbir Singh(Government Medical College, Amritsar, Punjab, India)0000-0003-1884-9291
Mahima Kamble(Avalon University School of Medicine, Willemstad, Curaçao)0009-0002-7915-9104
Jinpyo Hong(Penn State College of Medicine, Hershey, PA 17033)0009-0004-9256-9233
Mayank Dhalani(GMERS Medical College and Hospital, Gotri)0009-0003-8823-6076
Vasu Bansal(University of Missouri, Kansas City, Missouri)0000-0002-3865-8559
Rohit Jain(Avalon University School of Medicine)0000-0002-9101-2351
Pages
—
Publication Date
2026-07-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition.
📊
Key Findings & Data:Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration.
💡
Conclusion & Impact:Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Hemophilia A · Hemophilia B · Factor VIII

Abstract

Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage. Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies. Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation. Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.

🔖

Cite This Article

Senthil, A., Paul, T., Singh, K., Kamble, M., Hong, J., Dhalani, M., Bansal, V., Jain, R. (2026). Advances in Hemophilia Therapy: From Conventional Factor Replacement Therapy, Extended Half-Life (EHL) Products to Non-Factor and Gene-Based Therapies. Turkish Journal of Internal Medicine, Volume: 8. https://doi.org/10.46310/tjim.1972839

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (63)

  1. López-Arroyo JL, Pérez-Zúñiga JM, Merino-Pasaye LE, Martínez-Murillo C, Jaloma-Cruz AR, Quintana-González S, et al. Consensus on hemophilia in Mexico. Gac Med Mex. 2021;157 Suppl 1:S1-35. doi:10.24875/GMM.M21000463.
  2. Haider MZ, Anwer F. Acquired hemophilia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
  3. Mehta P, Reddivari AKR. Hemophilia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
  4. Bordbar M, Beigipour R, Tahami M, Zekavat OR, Haghpanah S, Moshfeghinia R. Skeletal complications in patients with hemophilia: a single-center experience. J Orthop Surg Res. 2023;18:907. doi:10.1186/s13018-023-04409-w.
  5. Fischer K, Bom JG, Mauser-Bunschoten EP, Roosendaal G, Berg HM. Effects of hemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia. 2005;11(1):43-8. doi:10.1111/j.1365-2516.2005.01065.x.
  6. Zhang H, Huang J, Kong X, Ma G, Fang Y. Health-related quality of life in children with hemophilia in China: a 4-year follow-up prospective cohort study. Health Qual Life Outcomes. 2019;17:28. doi:10.1186/s12955-019-1083-3.
  7. Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022;9(9):e689-97. doi:10.1016/S2352-3026(22)00209-5.
  8. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth. 2014;113(6):922-34. doi:10.1093/bja/aeu158.
  9. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. doi:10.1111/hae.14046.
  10. Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016;2016(1):657-62. doi:10.1182/asheducation-2016.1.657.
  11. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335-44. doi:10.1182/blood-2011-08-369132.
  12. Hart DP, Matino D, Astermark J, Dolan G, d’Oiron R, Hermans C, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022;13:20406207221085202. doi:10.1177/20406207221085202.
  13. von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388(4):310-8. doi:10.1056/NEJMoa2209226.
  14. Konkle BA, Nakaya Fletcher S. Hemophilia A. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. 2000 Sep 21.
  15. Konkle BA, Nakaya Fletcher S. Hemophilia B. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. 2000 Oct 2.
  16. Chaudhry R, Killeen RB, Babiker HM. Physiology, coagulation pathways. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
  17. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58(5):515-23. doi:10.4103/0019-5049.144643.
  18. Chowdary P, Carcao M, Kenet G, Pipe SW. Hemophilia. Lancet. 2025;405(10480):736-50. doi:10.1016/S0140-6736(24)02139-1.
  19. Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702-9. doi:10.3324/haematol.2019.221093.
  20. Giraud R, Delmotte N, Gensollen S, Roche M, Falaise C, Chambost H, et al. Recombinant factor VIII Fc fusion protein (rFVIIIFc) in real life: one-year clinical and economic outcomes. Drugs Real World Outcomes. 2021;8(4):527-35. doi:10.1007/s40801-021-00259-2.
  21. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231-42. doi:10.1182/blood.2020009217.
  22. Lewandowska M, Nasr S, Shapiro AD. Therapeutic and technological advancements in hemophilia care: quantum leaps forward. Haemophilia. 2022;28 Suppl 4:77-92. doi:10.1111/hae.14531.
  23. Matino D, Palladino A, Taylor CT, Sidonio RF Jr, Young G, Oldenburg J, et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025;146(14):1654–63. doi:10.1182/blood.2024027468.
  24. Young G, Kavakli K, Klamroth R, Matsushita T, Peyvandi F, Pipe SW, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025;145(25):2966-77. doi:10.1182/blood.2024027008.
  25. Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231-47. doi:10.1146/annurev-med-043021-033013.
  26. Kaczmarek R, Miesbach W, Ozelo MC, Chowdary P. Current and emerging gene therapies for haemophilia A and B. Haemophilia. 2024;30 Suppl 3:12-20. doi:10.1111/hae.14984.
  27. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706-18. doi:10.1056/NEJMoa2211644.
  28. Anguela XM, High KA. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. Blood Adv. 2024;8(7):1796-803. doi:10.1182/bloodadvances.2023010511.
  29. Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, et al. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv. 2021;5(7):1954-62. doi:10.1182/bloodadvances.2020003424.
  30. Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24(7):632-42. doi:10.18553/jmcp.2018.24.7.632.
  31. Zhou Y, Li Z, Liu G, Chen Z, Yao W, Li G, et al. Cost-effectiveness analysis of prophylaxis versus on-demand treatment for children with moderate or severe hemophilia A in China. Clin Ther. 2024;46(12):1010-5. doi:10.1016/j.clinthera.2024.09.003.
  32. Centers for Disease Control and Prevention. Hemophilia data & statistics. Atlanta (GA): Centers for Disease Control and Prevention; 2025 [cited 2026 Jul 24]. Available from: https://www.cdc.gov/hemophilia/data-research/index.html.
  33. Lim MY. How do we optimally utilize factor concentrates in persons with hemophilia? Hematology Am Soc Hematol Educ Program. 2021;2021(1):206-14. doi:10.1182/hematology.2021000310.
  34. Goedhart TMHJ, Janssen A, Mathôt RAA, Cnossen MH, OPTI-CLOT Study Group and SYMPHONY Consortium. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders: identifying knowledge gaps by mapping barriers and facilitators. Blood Rev. 2023;61:101098. doi:10.1016/j.blre.2023.101098.
  35. Ozelo MC, Hermans C, Carcao M, Guillet B, Gu J, Guerra R, et al. The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study. Ther Adv Hematol. 2024;15:20406207231218624. doi:10.1177/20406207231218624.
  36. Hermans C, Mancuso ME, Nolan B, Pasi KJ. Recombinant factor VIII Fc for the treatment of haemophilia A. Eur J Haematol. 2021;106(6):745-61. doi:10.1111/ejh.13610.
  37. Chang CY, Lai SW, Cheng MM, Ku JT, Hu SH, Liu YL, et al. Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy. Int J Hematol. 2023;117(3):378-87. doi:10.1007/s12185-022-03503-9.
  38. Keam SJ. Efanesoctocog alfa: first approval. Drugs. 2023;83(7):633-8. doi:10.1007/s40265-023-01866-9.
  39. Konkle BA. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A. Expert Rev Hematol. 2023;16(8):567-73. doi:10.1080/17474086.2023.2223925.
  40. Hahn SM, Han JW, Kim JS, Shim YJ, Kim S, Kim HC, et al. Real-world data for the use of emicizumab in haemophilia A patients with inhibitors: first nationwide report from Korea. Haemophilia. 2023;29(4):1163-6. doi:10.1111/hae.14819.
  41. Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021;27(5):854-65. doi:10.1111/hae.14363.
  42. Tory SS, Ghosh S, Nazneen H, Farhad N, Islam S, Hasan MJ, et al. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: a single-center experience in Bangladesh. eJHaem. 2024;5:39-46. doi:10.1002/jha2.832.
  43. Liu G, Huang K, Li G, Zhen Y, Li Z, Chen Z, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China. Front Pediatr. 2022;10:992267. doi:10.3389/fped.2022.992267.
  44. Levy-Mendelovich S, Brutman-Barazani T, Budnik I, Avishai E, Barg AA, Levy T, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med. 2021;10(19):4303. doi:10.3390/jcm10194303.
  45. Garcia J, Hammer MR, Zia A. Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis. Res Pract Thromb Haemost. 2023;7(8):102238. doi:10.1016/j.rpth.2023.102238.
  46. Sun SX, Frick A, Balasa V, Roberts JC. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A. Expert Rev Hematol. 2022;15(10):943-50. doi:10.1080/17474086.2022.2112171.
  47. Escobar M, Bullano M, Mokdad AG, Caicedo J, Schultz BG, Fan Q, et al. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol. 2023;16(6):467-74. doi:10.1080/17474086.2023.2198207.
  48. Pipe SW, Dunn AL, Young G. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2023;16(10):715-29. doi:10.1080/17474086.2023.2248385.
  49. Young G, Lenting PJ, Croteau SE, Nolan B, Srivastava A. Antithrombin-lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023;7(4):100179. doi:10.1016/j.rpth.2023.100179.
  50. Polderdijk SGI, Adams TE, Ivanciu L, Camire RM, Baglin TP, Huntington JA. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood. 2017;129(1):105-13. doi:10.1182/blood-2016-05-718635.
  51. Jiang M, Yang F, Jiang Y, Cheng L, Han J, Yi J, et al. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models. Blood. 2023;142(12):1071-81. doi:10.1182/blood.2023020005.
  52. Lentz SR, Chowdary P, Gil L, López-Jaime FJ, Windyga J, Ong Clausen WH, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024;22(4):990-1000. doi:10.1016/j.jtha.2023.12.016.
  53. VandenDriessche T, Pipe SW, Pierce GF, Kaczmarek R. First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy. Mol Ther. 2022;30(11):3335-6. doi:10.1016/j.ymthe.2022.09.020.
  54. Pasi KJ, Mitchell N, Kim B, Laffan M, Rangarajan S, Robinson TM, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27(6):947-56. doi:10.1111/hae.14391.
  55. Dhillon S. Fidanacogene elaparvovec: first approval. Drugs. 2024;84:479-86. doi:10.1007/s40265-024-02017-4.
  56. Cuker A, Kavakli K, Frenzel L, Wang JD, Astermark J, Cerqueira MH, et al. Gene therapy with fidanacogene elaparvovec in adults with hemophilia B. N Engl J Med. 2024;391(12):1108-18. doi:10.1056/NEJMoa2302982.
  57. Franchini M, Focosi D, Mannucci PM. How we manage cardiovascular disease in patients with hemophilia. Haematologica. 2023;108(7):1748-57. doi:10.3324/haematol.2022.282407.
  58. Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E, Tousoulis D. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2022;23(1):6. doi:10.3390/ijms23010006.
  59. Mohanty S, Casella M, Compagnucci P, Torlapati PG, La Fazia VM, Gianni C, et al. Oral anticoagulation and factor VIII replacement therapy in patients with hemophilia undergoing pulsed-field or radiofrequency catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2024;17(10). doi:10.1161/CIRCEP.124.012921.
  60. Rodriguez-Merchan EC. Pharmacological thromboprophylaxis in people with hemophilia experiencing orthopedic surgery: what does the literature say in 2023? J Clin Med. 2023;12(17):5574. doi:10.3390/jcm12175574.
  61. Schutgens REG, Jimenez-Yuste V, Escobar M, Mingot-Castellano ME, Chai-Adisaksopha C, Astermark J, et al. Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance. Hemasphere. 2023;7(6):e900. doi:10.1097/HS9.0000000000000900.
  62. Pipe SW, Trzaskoma B, Minhas M, Lehle M, Ko RH, Gao L, et al. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis. Res Pract Thromb Haemost. 2023;7(2):100077. doi:10.1016/j.rpth.2023.100077.
  63. Mahlangu J, Jiménez-Yuste V, Ventriglia G, Niggli M, Barlera S, Hermans C, et al. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Res Pract Thromb Haemost. 2024;8(2):102364. doi:10.1016/j.rpth.2024.102364.